You are here:

rivaroxaban (Xarelto)


Following a full submission

rivaroxaban (Xarelto®) is accepted for use within NHS Scotland for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.

In three large phase III studies in patients undergoing either total knee or total hip replacement surgery, rivaroxaban was superior to low molecular weight heparin in reducing the incidence of VTE and all cause mortality with patients while having a similar incidence of major bleeding events.

Drug Details

Drug Name: rivaroxaban (Xarelto)
SMC Drug ID: 519/08
Manufacturer: Bayer plc/Bayer Schering Pharma
Indication: Prevention of VTE in elective hip or knee replacement surgery
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 8 December 2008